Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
ACS Medicinal Chemistry Letters2010Vol. 1(3), pp. 130–134
Citations Over TimeTop 10% of 2010 papers
Shifeng Pan, Xu Wu, Jiqing Jiang, Wenqi Gao, Yongqin Wan, Cheng Dai, Dong Han, Jun Liu, Nathan Englund, Yan Wang, Stefan Peukert, Karen Miller‐Moslin, Jing Yuan, Ribo Guo, Melissa Matsumoto, Anthony Vattay, Yun Jiang, Jeffrey Tsao, Fangxian Sun, AnneMarie Culazzo Pferdekamper, Stephanie Dodd, Tove Tuntland, Wieslawa Maniara, Joseph F. Kelleher, Yung‐Mae Yao, Markus Warmuth, Juliet Williams, Marion Dorsch
Abstract
The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer. A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo). Structure-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Related Papers
- → Hedgehog signalling: how to get from Smo to Ci and Gli(2006)120 cited
- → Posttranscriptional Regulation of Smoothened Is Part of a Self-Correcting Mechanism in the Hedgehog Signaling System(2000)111 cited
- → Hedgehog: an unusual signal transducer(2004)92 cited
- → Expression of hedgehog signaling molecules in Merkel cell carcinoma(2009)44 cited
- → Smoothened overexpression activates hedgehog signaling in human hepatocarcinogenesis(2006)